MTRR and breast carcinoma: In some case-control studies, certain polymorphisms in fibroblast growth factor receptor 2 (FGFR2) and methionine synthase reductase (MTRR) were indicated to elevate individual susceptibility in postmenopausal breast cancer [35]–[37].